Detalles de la búsqueda
1.
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Diabetes Obes Metab;
26(6): 2128-2138, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38497241
2.
Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease.
Am J Nephrol;
55(2): 262-272, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37903483
3.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Lancet;
403(10424): 379-390, 2024 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38109916
4.
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Kidney Int;
104(6): 1219-1226, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37657768
5.
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Cardiovasc Diabetol;
22(1): 251, 2023 09 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37716952
6.
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab;
25(12): 3724-3735, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37671609
7.
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
BMJ Open Diabetes Res Care;
11(3)2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37311602
8.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Diabetes Obes Metab;
25(8): 2151-2162, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37161691
9.
Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.
Diabetes Obes Metab;
25(8): 2419-2422, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37157922
10.
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
Diabetes Obes Metab;
25(8): 2218-2226, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37232058
11.
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Am J Kidney Dis;
82(1): 84-96.e1, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36889425
12.
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.
Eur Heart J;
44(13): 1157-1166, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36691956
13.
Longitudinal relationship between albuminuria in infancy and childhood.
Pediatr Nephrol;
38(8): 2897-2900, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36705757
14.
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
J Am Heart Assoc;
11(16): e025045, 2022 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35929472
15.
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease.
Clin Pharmacol Ther;
112(5): 1098-1107, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35892316
16.
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
JACC Heart Fail;
10(7): 498-507, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35772861
17.
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
Diabetes Obes Metab;
24(8): 1429-1438, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35491532
18.
Endothelin Receptor Antagonists for Kidney Protection: Lessons from the SONAR Trial.
Clin J Am Soc Nephrol;
17(6): 908-910, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35483734
19.
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
Diabetes Metab;
48(4): 101331, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172198
20.
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Am J Kidney Dis;
79(2): 244-256.e1, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34029680